HOFSETH BIOCARE ASA: årsregnskap 2022 vs 2021
Grew 36% on revenue
approved 2023-03-30; registry 2023-08-02; journal 2023 638153
Summary
What changed
Comparing Årsregnskap 2022 with 2021 for HOFSETH BIOCARE ASA. Revenue 88.05m NOK → 119.96m NOK (+36.2%). Net result -122.24m NOK → -119.37m NOK. Equity 142.76m NOK → 167.8k NOK.
On the constructive side: revenue rose. Pressures included: operating result weakened; equity eroded; cash fell.
Also worth watching: paid-in equity reduced; payroll increased; book investments changed. All figures are taken from the published annual accounts for HOFSETH BIOCARE ASA.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 88.05m NOK to 119.96m NOK (+36.2% YoY). Calculated
What deteriorated
-
↓
Operating result weakened
Operating result -110.71m NOK → -112.61m NOK (op. margin -125.7% → -93.9%). Calculated
-
↓
Equity eroded
Book equity 142.76m NOK → 167.8k NOK (equity ratio 36.2% → 41.7%). Calculated
-
↓
Cash fell
Bank deposits 48.36m NOK → 31.34m NOK (-35.2% YoY). Calculated
Things to notice
-
·
Paid-in equity reduced
Paid-in equity fell 142.76m NOK → 167.8k NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
Payroll increased
Salary cost 37.80m NOK → 47.21m NOK (43% → 39% of revenue). Calculated
-
·
Book investments changed
Investment / intangible book value 18.76m NOK → 18.09m NOK. Reported fact